Fentanyl - Single Drug Urine Test Panel Catalogue No. See Box label

For in vitro diagnostic use

The Fentanyl Urine Test Panel is a competitive binding, lateral flow immunochromatographic assay for itative and simultaneous detection of Fentanyl in human urine at a specified cutoff level for use in employment and insurance testing.

The test provides only preliminary test results. A more specific alternative analytical method should be used in order to obtain a confirmed result. Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) are preferred confirmatory methods

The test is not intended to distinguish between prescription drug or illicit drug use.

Professional judgment should be exercised with any drug test result, particularly when the preliminary result is

WHAT IS FENTANYL URINE TEST PANEL?

The Fentanyl Urine Test Panel is an immunochromatographic assay for the qualitative determination of Fentanyl in human urine.

WHAT IS THE CUT-OFF VALUE AND APPROXIMATE DETECTION TIME?

Drug (Identifier)	Calibrator	Cut-off level	Minimum detection time	Maximum detection time
Fentanyl (FTY)	Fentanyl	200 ng/mL	1-4 hours	1-3 days

WARNINGS AND PRECAUTIONS

Not to be used for clinical diagnosi

- This kit is for external use only. Do not swallow
- Discard after first use. The test cannot be used more than once.
- Do not use test kit beyond expiry date
- Do not use the kit if the pouch is punctured or not sealed. Keep out of the reach of children
- Do not read after 5 minutes.

CONTENT OF THE KIT

Test devices, one test in one pouch. One pouch contains a test and a desiccant. The desiccant is for storage purposes only, and is not used in the test procedures. Leaflet with instructions for use

MATERIAL REQUIRED BUT NOT PROVIDED

- Urine collection cup
- Timer or clock

STORAGE AND STABILITY

Store at 4°C-30°C (40°F-86°F) in the sealed pouch up to the expiration date Keep away from direct sunlight, moisture and heat DO NOT FREEZE.

SPECIMEN COLLECTION

WHEN TO COLLECT URINE FOR THE TEST?

The minimum detection time is 1-4 hours, urine samples may be collected 1-4 hours after the suspected drug use


HOW TO COLLECT LIBINE?

- Urinate directly into the urine collection cup. Urine samples may be refrigerated at 2°C-8°C (36°F-47°F) and stored up to forty-eight hours. For longer storage, freeze the samples at -20°C (-4°F) or below. Bring frozen or refrigerated samples to room temperature before testing. Previously frozen or
- refrigerated samples should be well-mixed before analysis. Cloudy specimens should be centrifuged before analysis
- Use only clear aliquots for testing

TEST PROCEDURE

Test should be in room temperature 18°C-30°C (65°F-86°F)

- Open the sealed pouch by tearing along the notch. Remove the test device from the pouch. Hold one side of the device with one hand. Use the other hand to pull out the cap and expose the
- absorbent end. Immerse the absorbent end into the urine sample for approximately 10 seconds. Make sure that the urine level is not above the marked line printed on the front of the device.
- Re-cap the device and lav it flat on a clean, drv. non-absorbent surface
- Read the drug test results at 5 minutes. Do not read results after 5 minutes



Note: Results after more than 5 minutes may be not accurate and should not be read.

READING THE RESULTS

Negative (-)


A colored band is visible in each control region and the appropriate test region. It indicates that the concentration of the corresponding drug of that specific test zone is zero or below the detection limit of the

Preliminary positive (+)

A colored band is visible in each control region. No color band appears in the appropriate test region. It indicates a preliminary positive result for the corresponding drug of that specific test zone

If a colored band is not visible in each of the control region or a color band is only visible in each of the test region, the test is invalid. Another test should be run to re-evaluate the specimen. If test still fails, please contact the distributor with the lot number

Note: There is no meaning attributed to line color intensity or width



A preliminary positive test result does not always mean a person took drugs and a negative test result does not always mean a person did not take drugs. There are a number of factors that influence the reliability of drug

Positive

IMPORTANT: The result you obtained is called preliminary for a reason. The sample should be tested by a laboratory in order to determine if a drug is actually present. Send any sample which does not give a negative result to a laboratory for further testing

What Is A False Positive Test?

The definition of a false positive test would be an instance where a substance is identified incorrectly by the Fentanyl Urine Test Panel. The most common causes of a false positive test are cross reactants. Certain foods and medicines, diet plan drugs and nutritional supplements may cause a false positive test result with this

What Is A False Negative Test?

The definition of a false negative test is that the initial drug is present but isn't detected by the Fentanyl Urine Test Panel, If the sample is diluted, or the sample is adulterated that may cause false negative result

TEST LIMITATIONS

- This test has been developed for testing urine samples only. No other fluids have been evaluated. DO NOT use this device to test anything but urine.
- 2 Adulterated urine samples may produce erroneous results. Strong oxidizing agents such as bleach (hypochlorite) can oxidize drug analytes. If a sample is suspected of being adulterated, obtain a new
- 3. This test is a qualitative screening assay. It is not designed to determine the quantitative concentration of drugs or the level of intoxication.

Note: The test provides only preliminary test results. A more specific alternative chemical method should be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) are preferred confirmatory methods. Professional judgment should be exercised with any drug test result, particularly when the preliminary result is positive

SUMMARY

Fentanyl is a potent, synthetic narcotic analgesic with a rapid onset and short duration of action. It was first synthesized by Janssen Pharmaceutica (Belgium) in the late 1950s, and it is approximately 100 times more potent than morphine. Fentanyl is a strong agonist at the µ-opioid receptors. Historically it has been used to treat breakthrough pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic in nbination with a benzodiazepine. Fentanyl is frequently given intrathecally as part of spinal anesthesia or epidurally for epidural anesthesia and analgesia

PRINCIPI F

The Fentanyl Urine Test Panel is a competitive immunoassay that is used to screen for the presence of drugs in urine. It is chromatographic absorbent device in which drugs in a sample competitively combined to a limited number of drug monoclonal antibody (mouse) conjugate binding sites

When the absorbent end is immersed into urine specimen, the urine is absorbed into the device by capillary action, mixes with the respective drug monoclonal antibody conjugate, and flows across the pre-coated membrane. When sample drug levels are zero or below the target cutoff (the detection sensitivity of the test), respective drug monoclonal antibody conjugate binds to the respective drug-protein (duck egg) conjugate immobilized in the Test Region (T) of the device. This produces a colored Test line that, regardless of its intensity, indicates a negative result

When sample drug levels are at or above the target cutoff, the free drug in the sample binds to the respective drug monoclonal antibody conjugate preventing the respective drug monoclonal antibody conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents nent of a distinct colored band in the test region, indicating a potentially positive result.

To serve as a procedure control, a colored line will appear at the Control Region (C), where the Goat anti mouse IgG polyclonal antibody immobilized in, if the test has been performed properly

QUALITY CONTROL

Users should follow the appropriate federal, state, and local guidelines concerning the frequency of assaying external quality control materials.

Even though there is an internal procedural control line in the test device in the Control Region, the use of external controls is strongly recommended as good laboratory testing practice to confirm the test procedure and to verify proper test performance. Positive and negative controls should give the expected results. When testing the positive and negative controls, the same assay procedure should be adopted. External Control (positive and negative) should be run with each new lot of test received, each new shipment, each new operator and monthly to determine that tests are working properly. This will ensure that the end user has clear understanding of when to perform quality control testing.

PERFORMANCE CHARACTERISTICS

Accuracy

Eighty clinical urine specimens were analyzed by GC-MS and by the Fentanyl Urine Test Panel. Each test was ad by three viewers. Samples were divided by concentration into five categories: drug-free, less than half the cutoff, near cutoff negative, near cutoff positive, and high positive. Results were as follows:

Drug	Resul	t	Drug	Less	Near	Near	High	%Agreement wit
test			-free	than half	Cutoff	Cutoff	Positive	GC/MS
				the	Negativ	Positive	(greater	(95%CI)
				cutoff	е	(Betwee	than 50%	
				concentr	(Betwee	n the	above	
				ation by	n 50%	cutoff	the cutoff	
				GC/MS	below	and	concentr	
				analysis	the	50%	ation)	
					cutoff	above		
					and the	the		
					cutoff	cutoff		
					concentr	concentr		
					ation)	ation)		
FTY	Viewer	+	0	0	1	18	22	100% (84.5% - 100
	А	-	10	12	17	0	0	97.5% (82% - 100%
	Viewer	+	0	0	1	18	22	100% (84.5% - 100
	В	-	10	12	17	0	0	97.5% (82% - 100%
	Viewer	+	0	0	1	18	22	100% (84.5% - 100
	С	-	10	12	17	0	0	97.5% (82% - 100%

Precision and Sensitivity

To investigate the precision and sensitivity, each drug sample was analyzed at the following concentrations cutoff - 100%, cutoff - 75%, cutoff - 50%, cutoff - 25%, cutoff, cutoff +25%, cutoff + 50%, cutoff + 75% and the cutoff + 100%. All concentrations were confirmed with GC-MS. The study was performed 2 runs /day and lasted 25 days using three different lots of the Fentanyl Urine Test Panel. Totally 3 operators participated in the study of the Fentanyl Urine Test Panel. Each of the 3 operators tests 2 aliquots at each concentration for each lot per day (2 runs/day), for a total of 50 determinations per concentration per lot of the Fentanyl Urine Test Panel.

Drug test	Approximate concentration of	Number of determinations	Results Negative/ Positive		
	sample (ng/mL)	per lot	Lot 1	Lot 2	Lot 3
FTY	0	50	50/0	50/0	50/0
	5	50	50/0	50/0	50/0
	10	50	50/0	50/0	50/0
	15	50	50/0	50/0	50/0
	20	50	4/46	5/45	5/45
	25	50	0/50	0/50	0/50
	30	50	0/50	0/50	0/50
	35	50	0/50	0/50	0/50
	40	50	0/50	0/50	0/50

Specificity and Cross Reactivity

To test the specificity of the test, the test device was used to test various drugs, drug metabolites and other components of the same class that are likely to be present in urine. All the components were added to drugfree normal human urine. The following structurally related compounds produced positive results with the test when tested at levels equal to or greater than the concentrations listed below

Items	Concentration (ng/mL)
ntanyl (FTY)	
rfentanyl	20
ntanyl	200

Effect of Urinary Specific Gravity

12 urine samples with density ranges (1.005-1.025) were collected and spiked with Fentanyl at 25% below and 25% above cutoff levels. Each sample was tested by three batches of the Fentanyl Urine Test Panel. Three laboratory assistants read the result per batch of the Fentanyl Urine Test Panel. The results demonstrate that varying ranges of urinary specific gravity do not affect the test result.

Effect of Urinary PH

Fei

The pH of an aliquot of negative urine pool was adjusted to a pH range of 4 to 9 in 1 pH unit increments and spiked with Fentanyl at 25% below and 25% above cutoff levels. Each sample was tested by three batches of the Fentanyl Urine Test Panel. Three laboratory assistants read the result per batch of the Fentanyl Urine Test Panel. The result demonstrates that varying range of pH do not interfere with the performance of the test.

Interfering Substances

Clinical urine samples may contain substances that could potentially interfere with the test. The following compounds were added to drug-free urine, urine with a drug concentration 25% below the cutoff, and urine with a drug concentration 25% above the cutoff for Fentanyl. All potential interferents were added at a tion of 100 µg/mL. None of the urine samples tested showed any deviation from the expected in

3-Acetylmorphine	Ketamine
Acetaminophen	Ketoconazole
Acetylcodeine	Lamotrigine
Aciclovir	Lansoprazole
Acid Reducer	Levofloxacin
Adrenalin Hydrochloride	Levonorgestrel
Airshield	Levothyroxine Sodium
Alprazolam	Lidocaine Hydrochloride
Aminophylline	Lisinopril
Amiodarone Hydrochloride	Lithium Carbonate
Amitriptyline	Liverite
Amlodipine Mesylate	Lofexidine Hydrochloride
Amoxicillin	Loperamide
Amphetamine	Loratadine
Ampicillin	Magnesium
Aripiprazole	Mega-T Plus
Aspirin	Methadone
Atomoxetine	Methylamphetamine
Atorvastatin	Metoprolol Tartrate
Atropine	Mifepristone

th	
)%)	
%)	
)%)	
%)	
)%)	
%)	



Barbital Benzovlecaonine Caffeine Captopril Carbamazepine Cefaclor Cefalexin Cefradine Ciprofloxacin Hydrochloride Citalopram Clarithromyci Clomipramine Clonazepam Clopidogrel Bisulfate Clozapine Cocaine Hydrochloride Codeine Phosphate Cortisone CVS Dayquil Dextromethorphan Hydrobromide Dextropropoxyphene Napsylate Diazepam Diclofenac Sodium Digoxin Diphenoxylate Hydrochloride Dirithromycir Domperidone Donamine Hydrochloride Doxepin Doxylamine Duloxetine Ecstasy Hydrochloride Enalapril Maleate Ephedrine Hydrochloride Esomeprazol Estrogen Estroven Extenze Fenofibrate Flunitrazepar Fluoxetine Hydrochloride Fluvoxamine Fuel Furosemide Gabapentir Glibenclamide Gliclazide Glipizide Glucosamine Chondroitin Glucose Haloperidol Heartburn Relief Hvdrochlorothiazide

Mirtazapin Montelukast Morphine Mosapride Naloxone Hydrochloride Naltrexone Hydrochloride Naproven Nifedinine Nikethamide limetazepan Nimodipine Nitrazepam Nitroglycerin Noscapine Olanzapine Omeprazole Oxazepam Oxycodone Acetar Pantoprazole Papaverine Penfluridol Penicillin V Potassium Pethidine Hydrochloride Phenobarbital Phentolamine Phenytoin Sodium Pholoodine Pioglitazone Hydrochloride Piracetam Pravastatin Sodium Prednisone Acetate Procaine Hydrochlorid Propranolol Hydrochloride Propylthiouracil Pseudoephedrine Hydrochloride Pseudoephedrine Hydrochloride Quetiapine Ranitidine Hydrochloride Rifampin Secobarbital Sertraline Hydrochloride Sildenafil Citrate Simvastatin Sinus&Allergy Spironolactone Tetracycline Thebaine Topiramate Tramadol Hydrochloride Trazodone Triamterene Valproate Sodium Venlafaxine Hydrochloride Vitamin B1 Vitamin B2 Vitamin C Zencore Plus2

Isosorbide Dinitrate BIBLIOGRAPHY OF SUGGESTED READING

I Caps

Ibuprofen

Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982. Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elservier Science Publishing Company, Inc., New York, 1988

Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR(ed): Drug Addiction I, New York, Spring - Verlag, 1977.

Harvey, R.A., Champe, P.C. Lippincotts Illustrated Reviews. Pharmacology. 91-95, 1992.

Hawwks RL, CN Chiang. Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monography 73, 1986 Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford University

Press 1983 McBay, A. J. Clin. Chem. 33,33B-40B, 1987.

INDEX OF SYMBOLS



Keep away from sunlight

Store between 4°C - 30°C (40°F - 86°F)



Do not re-use

In vitro diagnostic use

Distributed by: Alere Toxicology Services Portsmouth, VA 23704 USA